新型心脏器官分配体系下以HeartMate 3左心室辅助装置桥接移植:个体化策略
研究基于UNOS登记数据库,纳入2010—2020年等待心脏移植的成人患者,比较新旧心脏分配体系下使用HeartMate 3左心室辅助装置(HM 3)桥接移植的结局。2017—2020年,FDA批准耐久性左心室辅助装置的等待名单患者数下降28.3%;新旧体系下移植累积发生率与死亡或病情恶化除名率相当。作者认为,在严格筛选的患者中,HM 3桥接移植仍是安全策略,桥接决策应基于患者危险因素个体化制定。
要点
- 2017—2020年,FDA批准耐久性左心室辅助装置的等待名单患者数下降28.3%
- 新旧分配体系下列表后1年移植累积发生率为53.4% vs 50.7%(p=0.76)
- 死亡或病情恶化除名率为5.0% vs 4.2%(p=0.43)
核心结论
- 在新心脏分配体系下,耐久性装置作为桥接移植的使用减少,但在严格筛选的患者中,以HM 3左心室辅助装置桥接仍是安全策略。
- 桥接决策应基于患者危险因素进行个体化制定。
研究设计与样本
- 查询美国器官共享联合网络(UNOS)登记数据库,纳入2010—2020年列名等待心脏移植的成人患者(≥18岁)。
- 比较新分配体系前与后耐久性左心室辅助装置使用趋势及HM 3左心室辅助装置患者的结局。
- 新分配体系前有449例患者以HM 3列名等待,新分配体系后有1094例。
主要发现
- 2017—2020年,FDA批准耐久性左心室辅助装置的等待名单患者数下降28.3%。
- 以HM 3左心室辅助装置列名后1年,移植累积发生率在新分配体系前为53.4%,新分配体系后为50.7%(p=0.76)。
- 以HM 3左心室辅助装置列名后1年,死亡或病情恶化除名率在新分配体系前为5.0%,新分配体系后为4.2%(p=0.43)。
- 高龄(>50岁)、缺血性心力衰竭、功能状态差、肌酐升高(>1.3 mg/dL)、肺动脉高压(>3 WU)和肥胖(体重指数>33 kg/m2)是HM 3桥接移植后移植后移植物死亡的危险因素。
临床怎么用
- 作者认为,以HM 3左心室辅助装置桥接移植仍是严格筛选患者中的安全策略,桥接决策应基于患者危险因素个体化制定。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Following the MOMENTUM 3 trial and the discontinuation of the HeartWare HVAD, the HeartMate 3 LVAD (HM 3) has become the main durable device for bridging to transplantation; however, outcome of this strategy in the new heart allocation system is not well understood. METHODS: The United Network for Organ Sharing (UNOS) registry was queried to include adult patients (≥18 years old) listed for heart transplantation between 2010 and 2020. Trends in durable LVAD utilization and outcomes of patients with HM 3 LVAD were examined in the pre- vs post-heart allocation system. RESULTS: From 2017 to 2020, there was a 28.3% decline in the number of patients waitlisted with an FDA-approved durable LVAD. Overall, 449 patients were waitlisted with HM 3 in the pre-allocation era compared to 1094 patients in the post-allocation. Cumulative incidence of heart transplantation (53.4% vs 50.7%, p = 0.76) and death or delisting for worsening status (5.0%, vs 4.2%, p = 0.43) at 1-year after listing with HM 3 LVAD was comparable in the pre- vs post-allocation era. Old age (>50), ischemic HF, poor functional status, elevated creatinine (>1.3 mg/dL), pulmonary hypertension (>3 WU), and obesity (body mass index > 33 kg/m2) were predictors of post-transplant graft mortality after bridging with HM 3. CONCLUSIONS: While the utilization of durable devices as BTT have declined under the new heart allocation system, bridging with HM 3 LVAD remains a safe strategy in carefully selected patients. Bridging decision should be individualized based on patient risk factors.
引用
- Uriel MH, Clerkin KJ, Takeda K, et al. Bridging to transplant with HeartMate 3 left ventricular assist devices in the new heart organ allocation system: An individualized approach. J Heart Lung Transplant. 2022. PMID: 36272893. doi:10.1016/j.healun.2022.08.022
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。